Purchases are not available yet. You can browse the site and sign in.
Psilocybin Long QT & Arrhythmia Risk: Cardiac Screening · Microdosing College
Safety
Long QT and Arrhythmia History: Why Trials Screen the Heart's Electrics
By Microdosing College Editorial·Last updated August 30, 2026·7 min read
Psilocybin long QT arrhythmia risk sits at the intersection of two facts that are both true but easy to conflate: clinical trials routinely exclude people with cardiac-electrical vulnerabilities, and the direct evidence for psilocybin causing dangerous arrhythmias at realistic doses is very limited. Understanding the gap between precautionary trial exclusions and real-world everyday risk is what this article is for.
If you have a diagnosed long QT syndrome, a personal history of Torsade de Pointes, or you take medications flagged for QT prolongation, this is one of the most important safety pages on this site. Please use our screener before reading further.
What is the QT interval and why does it matter?
The QT interval is the stretch of time on an electrocardiogram (ECG) between the Q-wave (the start of ventricular depolarisation) and the T-wave (the end of ventricular repolarisation). In plain English, it is the electrical reset time between heartbeats. When that reset takes too long — a corrected QTc above roughly 450–500 ms depending on the guideline used — the heart becomes vulnerable to a rare but life-threatening arrhythmia called (TdP), which can degenerate into ventricular fibrillation.
Torsade de Pointes
Long QT syndrome can be congenital (inherited ion-channel mutations, most commonly in KCNQ1 or KCNH2/hERG) or acquired — the latter is usually drug-induced. Many common drugs prolong QT: certain antibiotics (fluoroquinolones, azithromycin), antipsychotics (haloperidol, quetiapine), antiemetics (ondansetron), and antidepressants such as citalopram at high doses. Risk multiplies when several QT-prolonging agents are combined, or when electrolyte imbalances (low potassium or magnesium) are present.
How do clinical psilocybin trials handle QT screening?
Most phase-II and phase-III psilocybin trials apply a standard cardiovascular exclusion: participants with a QTcF > 450 ms (or 460 ms in some protocols), a history of Torsade de Pointes, congenital long QT syndrome, or significant arrhythmia are excluded. This is the same exclusion applied to trials of many new CNS drugs — it reflects precautionary pharmacovigilance rather than evidence of a known psilocybin-specific danger.
A 2023 peer-reviewed review of cardiovascular safety in psychedelic medicine — published in Psychopharmacology — surveyed the available data and concluded that psilocybin's primary cardiac signals are transient blood pressure and heart rate elevations mediated by 5-HT2A receptor activation, not QT prolongation (Betzler et al., 2023, PMC10661823). The same review noted that hERG-channel inhibition (the molecular mechanism behind drug-induced QT prolongation) has been observed with psilocin in vitro, but only at concentrations substantially higher than those achieved during a normal therapeutic session. The authors concluded that the clinical relevance of this finding at therapeutic doses remains uncertain.
This distinction matters. Preclinical hERG assays are run at concentrations that may be orders of magnitude above what human tissue actually encounters. A positive in-vitro hERG signal alone does not mean a drug causes QT prolongation in people — but it does flag a signal that regulators and trial sponsors handle with caution until human pharmacokinetic data accumulate.
Psilocybin's actual cardiac profile: what the evidence shows
Psilocybin's primary cardiovascular effects are well-characterised from controlled trial data. Across multiple studies, the consistent finding is modest, transient increases in systolic blood pressure and heart rate peaking approximately 60–90 minutes after ingestion, at the height of subjective effects, and resolving without intervention. These are 5-HT2A-mediated and autonomic in origin.
The Betzler et al. 2023 review, which is the most comprehensive synthesis of psychedelic cardiovascular safety published to date, reviewed clinical trial adverse-event data across psilocybin, MDMA, ketamine, and LSD. For psilocybin specifically, no trial has reported a case of Torsade de Pointes or clinically significant QTc prolongation in a screened participant receiving a standard therapeutic dose. This is reassuring — but the screened nature of trial populations means it cannot be extrapolated to unscreened people with pre-existing QT vulnerability.
A separate concern sometimes discussed alongside QT involves 5-HT2B receptor activation and its association with cardiac valvulopathy — most famously seen with long-term fenfluramine use. Psilocybin does have 5-HT2B affinity, but the episodic, low-frequency dosing pattern of both microdosing and guided therapy is considered very different pharmacologically from the chronic 5-HT2B agonism behind drug-induced valvulopathy. We cover that topic in depth in psilocybin 5-HT2B valvular heart risk.
Drug interactions that compound QT risk
For people already taking QT-prolonging medications, the risk calculus changes — not because psilocybin itself necessarily prolongs QT, but because adding any pharmacologically active substance to a regimen of QT-prolonging drugs requires clinical judgement.
Several drug classes relevant to the Microdosing College audience carry QT-prolonging potential:
Tricyclic antidepressants (TCAs) — amitriptyline, clomipramine and others are moderate QT prolongers.
Antipsychotics — many carry QT warnings; haloperidol and quetiapine in particular.
Certain SSRIs at high doses — citalopram and escitalopram carry dose-dependent QTc prolongation warnings from the FDA and EMA.
Methadone — used in opioid maintenance therapy, methadone has one of the strongest QT-prolongation profiles of any commonly prescribed drug.
Ondansetron — a widely used antiemetic sometimes taken to manage nausea during psychedelic sessions, ondansetron itself carries a QT warning and should not be assumed safe to combine without cardiac assessment.
If you take any of the above — or any drug listed on credentialed resources such as CredibleMeds — a conversation with a cardiologist or prescribing physician is not optional before any psilocybin use. See our article on microdosing with heart conditions for broader cardiac context.
Who should seek cardiology clearance before any psilocybin use?
Based on the exclusion criteria used across published psilocybin trials and the pharmacological reasoning in the Betzler et al. 2023 review, the following groups warrant cardiology review before considering psilocybin in any form — including microdosing:
Diagnosed congenital long QT syndrome (types 1–3 or others), regardless of current symptom control.
Personal history of Torsade de Pointes or unexplained syncope under exertion.
QTcF > 450 ms on a recent resting ECG (roughly 460 ms for women using some guidelines).
Multiple concurrent QT-prolonging medications — especially combinations of two or more drugs from the list above.
Significant electrolyte disorders — chronic hypokalemia or hypomagnesemia amplify QT risk from any cause.
Structural heart disease with ventricular remodelling — hypertrophic cardiomyopathy, severe left-ventricular hypertrophy, and similar conditions alter repolarisation and may independently raise arrhythmia risk.
This list is not exhaustive, and it is not a substitute for clinical evaluation. Use the screener on this site to flag relevant factors; the output is designed to help you have a more focused conversation with a clinician, not to replace one.
Putting the risk in proportion
Precautionary exclusions in clinical trials serve a specific regulatory and safety function: they protect a study population and allow clean interpretation of results. They do not automatically mean that the excluded condition makes psilocybin categorically dangerous for everyone with that condition under all circumstances.
For a healthy adult with a normal ECG, no history of arrhythmia, and no QT-prolonging comedications, the current evidence does not suggest a meaningful psilocybin long QT arrhythmia risk. The hERG signal exists in vitro; no clinical TdP cases have been reported in screened trial populations; and the predominant cardiac effects remain blood pressure and heart rate elevation, not electrical instability.
For someone with known QT vulnerability, the picture is different — not because psilocybin is proven dangerous in that context, but because the evidence to rule out risk in that population is thin. In the absence of adequate data, caution is appropriate and cardiology consultation is the right step.
This is the logic behind the screening, and it is worth understanding clearly. No amount of reassurance from a harm-reduction website replaces an ECG and a conversation with a cardiologist if you have relevant history. Route any health decisions through a qualified clinician and start with our screener.
Does psilocybin actually prolong the QT interval?+
In-vitro studies show psilocin can inhibit hERG channels at high concentrations, but no published clinical trial has reported QTc prolongation or Torsade de Pointes in screened participants at standard therapeutic doses. The clinical relevance of the in-vitro signal at human therapeutic concentrations remains uncertain (Betzler et al., 2023).
Why do psilocybin trials exclude people with long QT syndrome?+
Trial exclusions follow standard regulatory pharmacovigilance practice for any new CNS drug with a preclinical hERG signal. They protect participants and keep results interpretable — they do not necessarily mean psilocybin is proven dangerous for everyone with long QT, but they do mean this population lacks adequate safety data.
I take methadone (or another QT-prolonging drug) — can I microdose?+
Methadone has one of the strongest QT-prolonging profiles of any commonly prescribed drug. Combining it with any pharmacologically active substance warrants clinical review. You should consult your prescribing physician and ideally a cardiologist before considering any psilocybin use, including microdosing.
Is ondansetron safe to take for nausea during a psilocybin session if I have borderline QTc?+
Ondansetron itself carries a QT-prolongation warning from regulatory agencies. It should not be assumed safe to combine with psilocybin in someone with borderline or elevated QTc without cardiac assessment. Discuss antiemetic options with your clinician.
What QTc value triggers exclusion in most psilocybin trials?+
Most published psilocybin trials exclude participants with a QTcF above approximately 450 ms (some use 460 ms for women). These thresholds are drawn from standard FDA and ICH E14 guidance for drug development and are not specific to psilocybin.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
